JPRN-UMIN000032989已完成1 期
Clinical trial of human (allogeneic) induced pluripotent stem cell-derived cardiomyocyte sheet for severe cardiomyopathy - Clinical trial of human (allogeneic) iPS cell-derived cardiomyocyte sheet for severe cardiomyopathy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Severe infection. 2)Alcoholic or drug addiction in recent six months 3)Malignancy 4)Virus infection(HIV,HBV,HCV,HTLV) 5)Pregnancy 6)Hypersensitivity 7)Contraindication(Immunosuppressant) 8)Others
研究者
相似试验
招募中
1 期
A phase I/II study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass graftingHeart failure with ischemic heart diseaseIschemic heart disease, Heart Failure, Coronary artery bypass grafting (CABG)JPRN-jRCT2033210163Kaneko Takehiko10
尚未招募
1 期
To know the efficacy of poly herbal compound in the management of irritable bowel syndromeCTRI/2021/12/038944Santanu pal
进行中（未招募）
1 期
A Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19EUCTR2020-005299-36-ITExeVir Bio BV279
进行中（未招募）
1 期
A Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19Subjects hospitalised for COVID 19MedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862EUCTR2020-005299-36-PTExeVir Bio BV279
进行中（未招募）
1 期
A Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19Subjects hospitalised for COVID 19MedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862EUCTR2020-005299-36-ROExeVir Bio279